X4 Pharmaceuticals, Inc. (XFOR)
4.055
+0.02
(+0.37%)
USD |
NASDAQ |
Aug 24, 16:00
4.055
0.00 (0.00%)
After-Hours: 20:00
X4 Pharmaceuticals Enterprise Value : 256.98M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 256.98M |
| August 20, 2026 | 256.02M |
| August 19, 2026 | 268.51M |
| August 18, 2026 | 273.32M |
| August 17, 2026 | 281.97M |
| August 14, 2026 | 274.28M |
| August 13, 2026 | 281.01M |
| August 12, 2026 | 281.01M |
| August 11, 2026 | 280.05M |
| August 10, 2026 | 277.16M |
| August 07, 2026 | 314.65M |
| August 06, 2026 | 269.47M |
| August 05, 2026 | 267.55M |
| August 04, 2026 | 281.01M |
| August 03, 2026 | 261.78M |
| July 31, 2026 | 251.21M |
| July 30, 2026 | 253.13M |
| July 29, 2026 | 253.13M |
| July 28, 2026 | 246.41M |
| July 27, 2026 | 247.37M |
| July 24, 2026 | 238.72M |
| July 23, 2026 | 252.17M |
| July 22, 2026 | 223.82M |
| July 21, 2026 | 223.34M |
| July 20, 2026 | 222.38M |
| Date | Value |
|---|---|
| July 17, 2026 | 235.83M |
| July 16, 2026 | 236.79M |
| July 15, 2026 | 243.52M |
| July 14, 2026 | 255.06M |
| July 13, 2026 | 257.94M |
| July 10, 2026 | 292.54M |
| July 09, 2026 | 249.29M |
| July 08, 2026 | 249.29M |
| July 07, 2026 | 247.37M |
| July 06, 2026 | 256.02M |
| July 02, 2026 | 265.63M |
| July 01, 2026 | 261.30M |
| June 30, 2026 | 317.53M |
| June 29, 2026 | 242.51M |
| June 26, 2026 | 222.70M |
| June 25, 2026 | 219.87M |
| June 24, 2026 | 229.30M |
| June 23, 2026 | 220.81M |
| June 22, 2026 | 232.13M |
| June 18, 2026 | 241.56M |
| June 17, 2026 | 225.53M |
| June 16, 2026 | 224.58M |
| June 15, 2026 | 228.36M |
| June 12, 2026 | 220.81M |
| June 11, 2026 | 209.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics, Inc. | 2.242B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
| Anixa Biosciences, Inc. | 111.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.16M |
| Revenue (Quarterly) | 8.806M |
| Total Expenses (Quarterly) | 24.96M |
| EPS Diluted (Quarterly) | -0.1279 |
| Gross Profit Margin (Quarterly) | 81.24% |
| Profit Margin (Quarterly) | -183.5% |
| Earnings Yield | -29.44% |
| Normalized Earnings Yield | -29.25 |